McClellan on PAT
This article was originally published in The Tan Sheet
Executive Summary
FDA will publish draft guidance on process analytical technology in September, Commissioner Mark McClellan, MD/PhD, tells Product Quality Research Institute workshop participants on Aug. 5. "I hope you will all have a chance in September...to read our new guidance document that we will be releasing on the use of process analytical technology in making possible innovations in drug manufacturing and quality assurance," he says. The draft guidance is expected to draw from the agency's existing guidance on 21 CFR Part 11 electronic record/electronic signatures (1"The Tan Sheet" Oct. 28, 2002, p. 12)...
You may also be interested in...
PAT Guidance Will Draw From Existing Electronic Records Guidances
FDA plans to draw from existing guidances to clarify 21 CFR Part 11 electronic record/electronic signature requirements in its planned PAT guidance
Post-Brexit UK Risks Being ‘Left Out In The Cold’ As EU Coordinates Action On Shortages
The UK is not alone in experiencing drug shortages, as data from across Europe show, but its departure from the EU makes it more difficult to respond to supply chain pressures, according to new research.
Dr Reddy’s Knocked Back On Rituximab In US
Dr Reddy’s has received a complete response letter from the US FDA, knocking back its proposed rituximab biosimilar rival to Rituxan.